Ventura Cannabis and Wellness Corp CVHIF

Healthcare Drug Manufacturers - Specialty & Generic

Ventura Cannabis and Wellness Corp is a vertically integrated, California-based products cannabis company. The company is currently building out its distribution channel through revenue-sharing agreements with owner-operator of cannabis dispensaries to ensure it's products get premium shelf space. The Company plans to target four segments in the U.S. cannabis and CBD market with products suited to their needs: senior citizens, upwardly mobile middle-aged female professionals, upwardly mobile middle-aged male professionals and individuals suffering from addiction.

GREY:CVHIF - Post by User

Ventura Cannabis and Wellness Corp > Selling assets to competitors is called LIQUIDATION!

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Aug 31, 2020 12:34am

106 Views

Post# 31477894

RE:RE:RE:Selling assets to competitors is called LIQUIDATION!

I won't be surprized if these bozos pivot again, out of cannabis and into god knows what. Look what old sister company Inspira is up to...

Brattle Street seeks U.S. medical device deals

2020-08-18 19:16 ET - News Release

Mr. Michael Dalsin reports

BRATTLE STREET INVESTMENT CORP. FOCUSES ON MEDICAL DEVICE INVESTMENT OPPORTUNITIES

Brattle Street Investment Corp. has interest in pursuing investment opportunities in the U.S. medical device and health care industry.

"The U.S. medical device industry, from design to manufacturing to distribution, is highly fragmented with thousands of small, fast-growing private companies with valuable intellectual property and generous margins. This fragmentation, along with the performance of the public markets, may make this particular industry ripe with opportunity to take advantage of a private to public arbitrage and deliver value to our investors," said chairman Michael Dalsin. "As an example of the public market performance, IHI (the I Shares Dow Jones Medical Device ETF) has appreciated roughly 19.4 per cent over the trailing 12 months, outperforming the S&P 500, which grew roughly 15.6 per cent during the same time."

The company encourages any investors who believe they have suitable opportunities for the company, specifically medical device companies already generating revenues in the U.S. market, to send more information to IR@inspirafin.com.

The company also announces that its directors have granted options to acquire up to 925,000 common shares of the company at 14 cents per share, exercisable for five years, to three directors, officers and employees.